2Oksenhendler E, Duarte M, Soulier J. et al. Multieentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients[J]. AIDS, 1996,10:61-67.
3Saeed-Abdul-Rahman I, AI-Amri AM. Castleman disease[J]. Korean J Hemato1,2012,47 : 163-177.
4Kurokawa T, Suzuki S, Kawaguchi K, I ah Castleman disease presenting with ophthalmie signs and symptomslJ]. Am J Ophthahnol, 1999,128:114-116.
5lbrahim K, Maghfior 1, Elghazaly A, et al. Successful treatment of steroid-refractory autoimnmne thrombocytopenia associated with Castleman disease with anti-CD-20 antibody (rituximab) [J]. Hemalol Oncol Stein Cell Ther,2011,4: 100-102.
6Hoffmann C, Schmid H, Muller M, et al. Improved oulcome with rituximab in patients with HIV-associated muhieentric[J]. Castleman disease. Blood,2011,118:3499-3503.
7Song SN, Tomosugi N, Kawabala H, et al. Down-regulation of hepeidin resulting from long-term treatmen! with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric. Castleman disease[J]. Blnod,2010,116:3627- 3634.
8Galeotti C, Boueheron A, (,uillaume S, et al. Sustained remission of multicentric Castleman disease in children treated with tocilizumab, an anti-interleukin-6 receptor antibody[J]. Mol Cancer Ther,2012, 1 1 : 1623-1626.
2Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study) : evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis, 2009,68(10):1580-1584.
3Casquero A, Barroso A, Fem6ndez Guerrero ML, G6rgolas M. Use of rituximab as a salvage therapy forHIV-associated muhieentric Castleman disease. Ann Hematol, 2006, 85 (3): 185-187.
4Starkey CR, Joste NE, Lee FC. Near-total resolution of multicentric Castleman disease by prolonged treatment with thalidomide. Am J Hematol, 2006, 81 (4) : 303- 304.
